Drugs / Parathyroid Hormone (1-34)
Parathyroid Hormone (1-34)
also known as
hPTH 1-34 · PTH (1-34) · human parathyroid hormone(1-34) · PTH · Teriparatide (brand name: Forteo)
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00377312 | Sep 2006 → Dec 2007 | hyperparathyroidism, osteoporosis | University of Pittsburgh | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT05164614 | Feb → Oct 2022 | — | RANI Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01333267 | Jan 2015 → Jul 2017 | humoral hypercalcemia of malignancy, hyperparathyroidism, osteoporosis | University of Pittsburgh | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00004993 | Aug 1999 → Aug 2001 | osteoporosis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00853723 Comparator | May 2009 → Feb 2012 | osteoporosis | University of Pittsburgh | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Parathyroid Hormone (1-34) | “Parathyroid hormone (1-34), when given as a daily injection has been found to dramatically increase bone mass in osteoporotic animals and postmenopausal women.” NCT00004993 ↗4“A Phase I Study to Evaluate the Pharmacokinetics of Parathyroid Hormone (1-34) Administered Orally Via RaniPill™ Capsule” NCT05164614 ↗ |
| Known as | hPTH 1-34 | “We therefore developed 7-day continuous-infusion models using human parathyroid hormone(1-34) [hPTH(1-34)] and human parathyroid hormone-related protein(1-36) [hPTHrP(1-36)] in...” PMID 21544866 ↗ Sep 20111“Parathyroid hormone (hPTH 1-34)” NCT00004993 ↗ |
| Known as | human parathyroid hormone(1-34) | “We therefore developed 7-day continuous-infusion models using human parathyroid hormone(1-34) [hPTH(1-34)] and human parathyroid hormone-related protein(1-36) [hPTHrP(1-36)] in...” PMID 21544866 ↗ Sep 2011 |
| Known as | PTH | “evaluating the pharmacokinetics (PK) of human parathyroid hormone (1-34) ("PTH") administered via the RaniPill™ capsule ("RT-102")” NCT05164614 ↗ |
| Known as | PTH (1-34) | “There is only one anabolic agent that is presently approved by the FDA for treatment for osteoporosis: parathyroid hormone, PTH (1-34), or teriparatide.” NCT00853723 ↗1“PTH(1-34) IV given over a one week period” NCT00377312 ↗ |
| Known as | Teriparatide (brand name: Forteo) | “Teriparatide (brand name: Forteo)” NCT00853723 ↗ |
| Action | Activate | “Both peptides bind to the same receptor, PTH-1 R, and activate downstream signaling pathways” NCT00853723 ↗ |
| Modality | Peptide | “Both peptides bind to the same receptor, PTH-1 R, and activate downstream signaling pathways” NCT00853723 ↗ |
| Route | Intravenous | “PTH(1-34) IV given over a one week period” NCT00377312 ↗ |